Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by dacha8881on Apr 26, 2010 11:45am

521 Views

Post# 17031058

ugly

Does this say something about their trials? Hope not!!!

Last:
5.17
Volume:
170,470
Quote as of: 26 Apr 2010 11:42 AM ET

Change:
-0.60
Change (%):
-10.40
Bid:
5.11
Ask:
5.15
Bid Size:
5
Ask Size:
20
Day High:
5.80
Day Low:
5.06
# Orders
Shares
Bid
Ask
Shares
# Orders
3
500
5.110
5.150
2000
1
1
1000
5.100
5.170
1500
7
1
1000
5.080
5.180
1000
2
1
1600
5.060
5.200
800
2
2
1400
5.040
5.210
4100
1

Bullboard Posts

How to navigate the ups and downs of investing in AI